Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Assembly Biosciences, Inc

ASMB

Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.

Last trade $22.30
Day change +$1.01 (+4.72%)
Day range $21.12 – $22.58
Volume 176,136
Market cap $436M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$435.96M
Price / earnings
—
Price / book
1.46×
Price / sales
6.51×
EV / sales
6.07×
EV / EBITDA
-19.17×

Profitability

Earnings per share
-$0.54
Return on assets
-3.41%
Return on equity
-3.72%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
12.89×
Quick ratio
12.89×
Cash ratio
1.17×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$40.68M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ASMB, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$2.96M$13.37M$8.21M$42.47M$10.79M$9.63M$9.42M$7.36M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$2.96M$13.37M$8.21M$42.47M$10.79M$9.63M$9.42M$7.36M
Selling, general and administrative$6.14M$4.8M$4.68M$5.42M$5.09M$4.59M$4.51M$4.61M
Research and development$20.23M$14.92M$14.9M$17.25M$16.59M$16.13M$14.85M$14.28M
Total operating expenses$26.37M$19.72M$19.58M$22.67M$21.67M$20.72M$19.36M$18.89M
Operating income-$23.42M-$6.34M-$11.37M$19.8M-$10.88M-$11.09M-$9.94M-$11.53M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$20.26M-$3.86M-$9.08M$22.09M-$9.2M-$10.2M-$8.82M-$10.41M
Income taxes$0$0$0$0$0$0$0-$76K
Net income-$20.26M-$3.86M-$9.08M$22.09M-$9.2M-$10.2M-$8.82M-$10.34M
Net income attributable to common shareholders-$20.26M-$3.86M-$9.08M$22.09M-$9.2M-$10.2M-$8.82M-$10.34M
EBITDA-$23.39M-$6.32M-$11.34M$19.83M-$10.85M-$11.06M-$9.91M-$11.5M
Basic earnings per share-$0.93-$0.20-$0.54$1.30-$0.72-$1.33-$1.17-$1.58
Diluted earnings per share-$0.93-$0.20-$0.54$1.30-$0.72-$1.33-$1.17-$1.58

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Assembly Biosciences (ASMB) Reports Q3 Loss, Lags Revenue Estimates

Assembly Biosciences reported a quarterly loss of $0.93 per share, significantly worse than the consensus estimate of $0.44, representing a -111.36% earnings surprise. Revenue also missed expectations at $2.96 million versus consensus. The stock has declined 34.2% year-to-date and carries a Zacks Rank #3 (Hold) rating, expected to perform in line with the market.

Zacks Investment Research

Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks

Rising oil prices amid escalating Middle East tensions between the US and Iran are driving market volatility and inflation concerns. The Federal Reserve is expected to hike interest rates next month. Investors are rotating toward defensive stocks in consumer staples and healthcare sectors.

GlobeNewswire Inc.

Assembli to Produce Big Ten Conference Activation at Fanatics Fest in New York

Assembli has been selected to design and produce the Big Ten Conference's first-ever fan experience at Fanatics Fest NYC (July 16-19, 2026), making the Big Ten the first collegiate conference to participate in the event. The activation will feature the Heisman Trophy, CFP National Championship Trophy, interactive games, and fan engagement activities. Assembli will also return for its third consecutive year to produce the Big Ten Championship Fan Fest in December 2026.

GlobeNewswire Inc.

Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference

Assembly Biosciences announced that its Chief Medical Officer, Anuj Gaggar, MD, PhD, will present at the Bank of America Securities 2026 Global Health Care Conference on May 13, 2026. The company also highlighted positive Phase 1b data for its helicase-primase inhibitors ABI-5366 and ABI-1179 for recurrent genital herpes treatment, with additional data selected for oral presentation and late-breaker poster presentation at ESCMID Global 2026.

GlobeNewswire Inc.

Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

Assembly Biosciences reported Q1 2026 financial results with cash reserves of $226.6 million, sufficient to fund operations into 2028. The company completed Phase 1b studies for herpes candidates ABI-5366 and ABI-1179 (licensed to Gilead) and chronic toxicology studies for hepatitis delta virus candidate ABI-6250, with Phase 2 initiation expected in Q4 2026. Net loss was $9.1 million for the quarter.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Feb 12, 20241-for-12reverse split